

# Jeppe Romme Christensen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6093495/publications.pdf>

Version: 2024-02-01

29  
papers

1,534  
citations

516710

16  
h-index

477307

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

3031  
citing authors

#	ARTICLE	IF	CITATIONS
1	Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7T MRI study. <i>Brain</i> , 2022, 145, 3522-3535.	7.6	6
2	Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102987.	2.0	11
3	Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1065.	6.0	1
4	Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	15
5	Imaging cortical multiple sclerosis lesions with ultra-high field MRI. <i>NeuroImage: Clinical</i> , 2021, 32, 102847.	2.7	8
6	Neurophysiological changes associated with cortical lesions in multiple sclerosis.. <i>Brain Stimulation</i> , 2021, 14, 1628.	1.6	0
7	Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101451.	2.0	18
8	Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102391.	2.0	11
9	Initial high-efficacy disease-modifying therapy in multiple sclerosis. <i>Neurology</i> , 2020, 95, e1041-e1051.	1.1	83
10	Pregnancy-Induced Changes in microRNA Expression in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 552101.	4.8	12
11	CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage. <i>Multiple Sclerosis Journal</i> , 2019, 25, 937-946.	3.0	32
12	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	9.0	455
13	GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis. <i>Journal of Autoimmunity</i> , 2019, 97, 114-121.	6.5	30
14	Progressive multiple sclerosis, cognitive function, and quality of life. <i>Brain and Behavior</i> , 2018, 8, e00875.	2.2	48
15	Smoking reduces circulating CD26hiCD161hi MAIT cells in healthy individuals and patients with multiple sclerosis. <i>Journal of Leukocyte Biology</i> , 2017, 101, 1211-1220.	3.3	17
16	Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis. <i>Cytokine</i> , 2017, 93, 15-25.	3.2	12
17	Defining active progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1727-1735.	3.0	34
18	Characterization of naïve, memory and effector T cells in progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 310, 17-25.	2.3	20

#	ARTICLE	IF	CITATIONS
19	Pneumococcal meningitis with normal cerebrospinal biochemistry and no pneumococci at microscopy, mimicking a stroke: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 150.	0.8	3
20	High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. <i>Multiple Sclerosis Journal</i> , 2017, 23, 675-685.	3.0	38
21	Absence of systemic oxidative stress and increased CSF prostaglandin F $2\pm$ in progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e256.	6.0	15
22	Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e191.	6.0	69
23	Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 926-934.	3.0	23
24	Endogenous Interferon- $\beta$ -Inducible Gene Expression and Interferon- $\beta$ -Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0118830.	2.5	18
25	Natalizumab in progressive MS. <i>Neurology</i> , 2014, 82, 1499-1507.	1.1	110
26	CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 877-884.	3.0	75
27	Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression. <i>PLoS ONE</i> , 2013, 8, e57820.	2.5	213
28	Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2012, 9, 215.	7.2	66
29	Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e47578.	2.5	59